RCEL Stock Analysis: Buy, Sell, or Hold?
RCEL - Avita Medical, Inc. Common Stock
$10.06
-0.03 (-0.30%)
▼
5d:
+28.15%
30d:
+118.22%
90d:
+124.55%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When RCEL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: RCEL is 37.8% above its trading range ($7.30). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: RCEL is 37.8% above its trading range ($7.30). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: RCEL is currently trading at $10.06, which is considered extended relative to its 30-day fair value range of $3.97 to $7.30. From a valuation perspective, the stock is trading at a discount (Forward PE: -16.2) compared to its historical average (8.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RCEL is in a uptrend. Immediate support is located at $7.39, while resistance sits at $10.41.
Market Sentiment: RCEL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RCEL is in a uptrend. Immediate support is located at $7.39, while resistance sits at $10.41.
Market Sentiment: RCEL scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.97 -
$7.30
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
16.7%
All Signals
- BEARISH: Price significantly overextended (+37.8% above its trading range)
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Trading above Wall St target ($9.07)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.97 -
$7.30
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.39
Resistance Level
$10.42
Current Trend
Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.22
Wall Street Target
$9.07
(-7.9%)
Revenue Growth (YoY)
17.8%
Profit Margin
-57.0%
PE vs Historical
-16.2 vs 8.0
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 1:28 AM ET
Data refreshes hourly during market hours. Next update: 2:28 AM
Data refreshes hourly during market hours. Next update: 2:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCEL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 48 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 31 SELL |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 37 SELL |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$98 | 35 SELL |
